C. Douglas While, OpGen CEO

GAITHERSBURG, MD – OpGen, Inc., a genomics solutions company, has named C. Douglas White CEO. He replaces Evan Jones, managing member of jVen Capital and previous co-founder, chairman and CEO of Digene Corporation, who held the position on an interim basis.

In conjunction with this appointment, Jones remains a member of OpGen’s board of directors, and White also joins the board.

White brings more than two decades of global leadership experience in clinical diagnostics, including senior executive roles with BG Medicine, QIAGEN, Digene, Bayer Diagnostics and Chiron Diagnostics.

Jones commented, “Doug was an integral part of our success at Digene, guiding strategy and maximizing the value of the company’s technology, and I am confident that his considerable experience will provide invaluable insights as we seek to maximize the potential of OpGen’s Optical Mapping technology.”

Prior to joining OpGen, Mr. White served as executive vice president and general manager for the diagnostics division of BG Medicine, a commercial-stage company focused on the discovery and application of novel biomarkers associated with cardiovascular disease, central nervous system and autoimmune disorders.

White served as chair of the Americas Management Council and senior vice president of sales and marketing, Americas, for QIAGEN, N.V. He also served as senior vice president commercial operations, Americas and Asia Pacific, for Digene Corporation, prior to the company’s $1.6 billion acquisition by QIAGEN in July 2007.